Skip to Main Content

Paper Details

Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
Gynecol Oncol
0
2023
Author NameAffiliation
Brian L HoodGynecologic Cancer Center of Excellence, Uniformed Services University and Walter Reed National Military Medical Center, USA Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Bethesda
Clifton L DalgardUniformed Services University
Kathleen M DarcyGynecologic Cancer Center of Excellence, Uniformed Services University and Walter Reed National Military Medical Center, USA Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Bethesda, USA The John P. Murtha Cancer Center
Christopher J BakkenistUniversity of Pittsburgh School of Medicine
George L MaxwellGynecologic Cancer Center of Excellence, Uniformed Services University and Walter Reed National Military Medical Center, USA The John P. Murtha Cancer Center
Thomas P ConradsGynecologic Cancer Center of Excellence, Uniformed Services University and Walter Reed National Military Medical Center, USA The John P. Murtha Cancer Center
  • 1 - 6

Datasets